Aqueous pharmaceutical composition containing moxifloxacin or salts thereof

1. An aqueous pharmaceutical formulation comprising moxifloxacin or a salt thereof and at least one isotonizing agent selected from the group consisting of sugars and sugar alcohols, characterized in that it comprises less than 10 ppb of iron.

2. An aqueous pharmaceutical formulation as claimed in claim 1 , characterized in that it comprises moxifloxacin or a salt thereof in an amount of from 0.02 to 2.4% (w/v) (based on the amount of moxifloxacin) and at least one of the isotonizing agents in such an amount that preparations having a tonicity of up to 350 mOsmol/kg are obtained.

3. The aqueous pharmaceutical formulation as claimed in claim 1 , characterized in that it comprises isotonizing agents in such an amount that solutions having a tonicity of from 270 to 330 mOsmol/kg are obtained.

4. The aqueous pharmaceutical formulation as claimed in any of claims 1 to 3 , characterized in that it comprises from 250 to 350 mmol/l of sugar.

5. The aqueous pharmaceutical formulation as claimed in any of claims 1 to 3 , characterized in that it comprises from 250 to 350 mmol/l of sugar alcohol.

6. The aqueous pharmaceutical formulation as claimed in any of claims 1 to 3 , characterized in that it comprises from 0 to 350 mmol/l of sugar alcohol and from 350 to 0 mmol/l of at least one monosaccharide or oligosaccharide.

7. The aqueous pharmaceutical formulation as claimed in any of claims 1 to 3 , characterized in that it comprises glucose as isotonizing agent.

8. The aqueous pharmaceutical formulation as claimed in any of claims 1 to 3 , characterized in that it is prepared using at least one monosaccharide or oligosaccharide, the iron contents of which are less than 6.5×10 −4 mmol/mol of monosaccharide or oligosaccharide.

9. The aqueous pharmaceutical formulation as claimed in any of claims 1 to 3 , characterized in that it is prepared using sugar alcohol, the iron content of which is less than 6.5×10 −4 mmol/mol of sugar alcohol.

10. An aqueous pharmaceutical formulation as claimed in any of claims 1 to 3 , characterized in that it comprises moxifloxacin hydrochloride.

11. An aqueous pharmaceutical formulation as claimed in any of claims 1 to 3 for parenteral administration to humans and animals.

12. An aqueous pharmaceutical formulation of moxifloxacin or a salt thereof comprising a monosaccharide, the iron content of which is less than 6.5×10 −4 mmol/mol of monosaccharide.

13. An aqueous pharmaceutical formulation of moxifloxacin or a salt thereof comprising a disaccharide, the iron content of which is less than 6.5×10 −4 mmol/mol of disaccharide.

14. A process for preparing an aqueous pharmaceutical formulation of moxifloxacin or a salt thereof, characterized in that at least one sugar alcohol, the iron content of which is less than 6.5×10 −4 mmol/mol of sugar alcohol, is used for the formulation.

15. A process for preparing an aqueous pharmaceutical formulation of moxifloxacin or a salt thereof, characterized in that monosaccharide(s), the iron contents of which are less than 6.5×10 −4 mmol/mol of monosaccharide(s), are used for the formulation.

16. A process for preparing an aqueous pharmaceutical formulation of moxifloxacin or a salt thereof, characterized in that disaccharide(s), the iron contents of which are less than 6.5×10 −4 mmol/mol of disaccharide(s), are used for the formulation.

17. A process for preparing an aqueous formulation of moxifloxacin or a salt thereof, wherein a solution of moxifloxacin or a salt thereof having a moxifloxacin concentration or moxifloxacin salt concentration of from more than 0.2% (w/v) to the saturation concentration at room temperature of moxifloxacin or the salt thereof is, using a sugar- or sugar-alcohol-containing infusion carrier solution, adjusted to a use concentration suitable for parenteral administration.

18. A process as claimed in claim 17 , wherein a solution of moxifloxacin hydrochloride having a concentration of from more than 0.2% (w/v) to 2.4% (w/v) (based on the amount of moxifloxacin) is used.

19. A pharmaceutical composition for parenteral administration comprising an aqueous solution of moxifloxacin hydrochloride in water having a moxifloxacin hydrochloride concentration (based on the amount of moxifloxacin) of from more than 0.2% (w/v) to 2.4% (w/v).

20. A combination preparation comprising an aqueous solution of moxifloxacin hydrochloride in water having a moxifloxacin hydrochloride concentration (based on the amount of moxifloxacin) of from more than 0.2% (w/v) to 2.4% (w/v) and an aqueous solution comprising sugar or sugar alcohols, wherein said solutions are separated from one another.

21. The aqueous pharmaceutical formulation as claimed in claim 4 , characterized in that it comprises glucose as isotonizing agent.

22. The aqueous pharmaceutical formulation as claimed in claim 4 , characterized in that it is prepared using at least one monosaccharide or oligosaccharide, the iron contents of which are less than 6.5×10 −4 mmol/mol of monosaccharide or oligosaccharide.

23. The aqueous pharmaceutical formulation as claimed in claim 5 , characterized in that it is prepared using sugar alcohol, the iron content of which is less than less than 6.5×10 −4 mmol/mol of sugar alcohol.

24. An aqueous pharmaceutical formulation as claimed in claim 4 , characterized in that it comprises moxifloxacin hydrochloride.

25. An aqueous pharmaceutical formulation as claimed in claim 5 , characterized in that it comprises moxifloxacin hydrochloride.

26. An aqueous pharmaceutical formulation as claimed in claim 6 , characterized in that it comprises moxifloxacin hydrochloride.

27. An aqueous pharmaceutical formulation as claimed in claim 7 , characterized in that it comprises moxifloxacin hydrochloride.

28. An aqueous pharmaceutical formulation as claimed in claim 8 , characterized in that it comprises moxifloxacin hydrochloride.

29. An aqueous pharmaceutical formulation as claimed in claim 9 , characterized in that it comprises moxifloxacin hydrochloride.

30. An aqueous pharmaceutical formulation as claimed in claim 4 for parenteral administration to humans and animals.

31. An aqueous pharmaceutical formulation as claimed in claim 5 for parenteral administration to humans and animals.

32. An aqueous pharmaceutical composition as claimed in claim 6 for parenteral administration to humans and animals.

33. An aqueous pharmaceutical composition as claimed in claim 7 for parenteral administration to humans and animals.

34. An aqueous pharmaceutical composition as claimed in claim 8 for parenteral administration to humans and animals.

35. An aqueous pharmaceutical composition as claimed in claim 9 for parenteral administration to humans and animals.